Materials and Methods
The tissue specimen was fixed in formalin and processed routinely for histopathology. Immunohistochemistry (IHC) was performed on 3-µm sections cut from paraffin blocks using a fully automated system (“Benchmark XT System”, Ventana Medical Systems Inc, 1910 Innovation Park Drive, Tucson, Arizona, USA) and the following antibodies: CK7 (OV-TL, 1:1000, Biogenex), p63 (SSI6, 1: 100, DCS), CK5 (clone XM26, 1: 50, Zytomed), EMA (E29, 1:20, Dako), CEA (polyclonal, 1:400, Dako), CK19 (RCK108, 1:300, Dako), p16 (clone JC8, 1:100, Santa Cruz Biotechnology), TP53 (DO-7, 1:50, Dako) and anti-NUT antibody (clone C52B1, 1:45, Cell Signaling).
Molecular Testing
DNA was extracted from formalin-fixed paraffin-embedded tumor tissue and tested for oncogenic Human Papillomavirus (HPV) infection using the methods described previously [
5]. RNA was isolated from formalin-fixed paraffin embedded (FFPE) tissue sections using RNeasy FFPE Kit of Qiagen (Hilden, Germany) and quantified spectrophotometrically using NanoDrop-1000 (Waltham, United States). Molecular analysis was performed using the TruSight RNA Fusion panel (Illumina, Inc., San Diego, CA, USA) with 500 ng RNA as input according to the manufacturer`s protocol. Libraries were sequenced on a MiSeq (Illumina, Inc., San Diego, CA, USA) with > 3 million reads per case, and sequences were analyzed using the RNA-Seq Alignment workflow, version 2.0.1 (Illumina, Inc., San Diego, CA, USA). The Integrative Genomics Viewer (IGV), version 2.2.13 (Broad Institute, REF) was used for data visualization.
Discussion
Primary salivary gland carcinomas with prominent squamous differentiation are rare. On the contrary, metastatic SCC presenting within the parotid gland is relatively common; the majority represent metastases from cutaneous head and neck SCC to intraparotid lymph nodes. In surgical series, SCC represented 6.6% of all parotid tumors and 41.5% of malignant cases [
4]. In the files of the Hamburger Salivary Gland Registry, 75 of 10,944 salivary gland neoplasms were parotid metastases (37 localized within the parotid parenchyma and 38 within intraparotid nodes) [
6]. Elderly men are predominantly affected at a mean age of 79.6 years [
4]. The site of the primary tumor in metastatic cases was predominantly the head and neck skin, less frequently the pharynx and other primary head and neck locations, and rarely other extra-head and neck sites [
4,
6]. Rare cases represented carcinomas of unknown primary [
4].
A rare subset of high-grade salivary duct carcinoma and carcinoma ex pleomorphic adenoma with basal-like phenotype may display variable degree of squamous differentiation mimicking SCC and should be excluded by thorough sampling and other defined morphological features [
7‐
9]. In the current case, there was no other tumor component, in particular no evidence of pre-existent pleomorphic adenoma or ductal differentiation. Moreover, RNA testing revealed no
PLAG1 or other gene fusions that would suggest origin from a pleomorphic adenoma.
NUT carcinoma may present rarely as primary salivary gland malignancy in the young age (adolescent and young adults) and it is therefore an important consideration [
10]. However, squamous differentiation is usually limited in NUT carcinoma, represented by small foci of abrupt squamous differentiation in a background of poorly differentiated or undifferentiated neoplasm [
10]. This possibility, however, is also excluded in the current case by negative NUT immunostaining and by absence of a
NUTM1 fusion at the molecular level. High-grade mucoepidermoid carcinoma is defined by
CTRC1/3-MAML2 fusion and histologically equivocal cases can be confirmed by molecular verification of the presence of the fusion [
11].
If all of the differential diagnostic possibilities discussed above are reliably excluded, primary SCC of the parotid gland is vanishingly rare and is considered a diagnosis of exclusion [
12]. In a recently published thorough literature review [
13], the annual incidence of primary parotid SCC was in the range of 1.54 to 2.8 cases per million. However, upon critical reassessment, 30–86% of those cases initially reported as primary parotid SCC were found to represent metastases from skin or from upper aerodigestive tract SCC, highlighting an even much lower incidence than initially thought [
13].
Thorough clinical workup supplemented by careful histopathological assessment is the only way to distinguish secondary metastatic SCC within the parotid from the vanishingly rare primary SCC. Distinguishing these two scenarios is of utmost clinical importance, given the significant differences in therapy and prognostication. However, there are currently no standard or reproducible criteria for confirming primary parotid SCC. Histological features proposed to be in favor of a primary parotid SCC include location within parotid parenchyma, absence of association with overlying skin, lack of mucin and intermediate cells and association with a duct or presence of squamous dysplasia in the ductal system [
12,
13]. The etiology of primary SCC of the parotid gland is poorly understood, due to the rarity of the disease and to frequent confusion with metastatic SCC. Longstanding ductal obstruction due to lithiasis with subsequent squamous metaplasia and dysplasia has been proposed as explanation for primary SCC of the parotid gland [
12].
The current case qualifies as SCC but showed unusual histological and clinical features leading to consideration of an alternative diagnosis: (1) the tumor presented at unusually young age (24 years in contrast to a mean age of 79 years for SCC of the parotid reported in the literature [
4]; (2) it shows adnexal-type keratinization and variable other features reminiscent of adnexal-type differentiation; and (3) no other primary tumor could be found by thorough clinical investigation. This prompted us to perform NGS-based molecular testing to exclude unusual variants of translocation-related malignancies which revealed the
YAP1-MAML2 gene fusion.
MAML2 is a coactivator of transcription that is involved in the upregulation of the notch pathway target genes [
14,
15].
MAML2 is a well characterized fusion partner involved in the pathogenesis of salivary mucoepidermoid carcinoma, where it is fused to either
CRTC1 or
CRTC3 [
15]. YAP1 on the other hand is a transcriptional coactivator involved in the regulation of the Hippo and Wnt pathways via TEAD-dependent mechanisms [
16].
YAP1-MAML2 gene rearrangements have been recently reported in rare nasopharyngeal carcinoma [
17], all of metaplastic thymomas in one study [
18] and in cell lines of diverse malignancies including glioblastoma, ovarian cancer and squamous cell carcinoma of the tongue [
16,
19].
A recent study utilizing RNA sequencing and reverse transcription PCR analysis revealed a surprisingly high frequency of recurrent
YAP1-MAML2 fusions and the reciprocal
MAML2-YAP1 fusions in 71/104 (68%) poromas and in 1/11 (9%) porocarcinomas, respectively [
20]. Poroma and porocarcinoma are rare skin adnexal neoplasms with features of terminal sweat duct differentiation [
21]. As the malignant counterpart of poroma, porocarcinoma develops either from preexistent benign poroma or de novo [
21]. The current case showed subtle features of conventional porocarcinoma including abortive ductal differentiation (highlighted by IHC) and adnexal-type keratinization associated with comedo-type necrosis [
21]. Although squamous differentiation is considered uncommon in porocarcinoma [
21], a predominantly squamoid variant has been proposed [
22]. The predominance of squamous differentiation in the current case qualifies the tumor as squamoid porocarcinoma. The best terminology for the current case (SCC variant with poroid or acrosyringial differentiation versus porocarcinoma with extensive squamous cell differentiation) remains an issue of future studies, looking for molecular homologies or differences between the two entities.
The exact histogenetic origin of the tumor we are reporting herein is unclear. Given that some translocation-driven carcinoma variants of presumed ductal origin are shared by both the salivary glands and the skin adnexa including in particular mucoepidermoid carcinoma and secretory carcinoma [
11,
15,
23], it is possible that this variant of salivary gland poroid SCC is of ductal origin as well, but this remains currently speculative.
As illustrated by the current case, age represents a strong clue to the differential diagnoses, in particular in unusually presenting neoplasms and is frequently suggestive of a genetically defined entity, hence warranting or justifying molecular testing. Indeed, all three possibilities in such a case of SCC-like malignancy of the salivary glands in a very young individual are translocation-driven: NUTM1-rearranged carcinoma, unusual variant of MAML2-related high-grade mucoepidermoid carcinoma and, based on the current case, YAP1-MAML2-driven squamous variant of porocarcinoma.
Distinguishing conventional cutaneous SCC from squamoid porocarcinoma of the skin is considered important in view of the different behavior of the two entities with regard to the higher risk for local recurrence, nodal involvement, systemic metastasis and overall mortality for porocarcinoma which is in contrast to the overall better outcome of conventional SCCs of the skin [
22]. However, data comparing the outcome of SCC of the parotid gland and cutaneous porocarcinoma are lacking. While there is no need for fusion testing in cutaneous and other head and neck SCC metastatic to the parotid lymph nodes, molecular analysis of any putative primary SCC in the parotid gland, especially in the young, is recommended. Currently available sparse data precludes any reliable statement regarding the specificity of the
YAP1-MAML2 fusion as surrogate for “primary or metastatic porocarcinoma” versus “primary conventional SCC” of the parotid gland.
In summary, this is the first case of YAP1-MAML2-rerranaged poroid SCC (predominantly squamous porocarcinoma) presenting as a primary parotid gland malignancy in a young adult in the absence of another primary tumor. Inclusion of this entity in the differential diagnosis is mandatory to avoid misdiagnosis as conventional SCC and will help to delineate the prognostic and therapeutic implications of this uncommon putative entity.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.